Treatment options for benign prostatic hyperplasia

Bibliography

• OESTERLING JE: Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. (1996) 6:67–73.
   PubMedGoogle Scholar
• ISAACS JT, COFFEY DS: Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. (1989) 2:33–50.
   PubMedGoogle Scholar
• BRUSKEWITZ RC: Benign prostatic hyperplasia: drug and nondrug therapies. Geriatrics (1992) 47(12):39–42, 45.
   PubMed Web of Science ®Google Scholar
• MCCONNELL JD, BARRY MJ, BRUSKEWITZ RC: Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin. Pract. Guidelines Quick Ref Guide Clin. (1994) 8:1–17.
   PubMedGoogle Scholar
• LOWE FC, MCDANIEL RL, CHMIEL JJ, HILLMAN AL: Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology (1995) 46(4)477–483.
   PubMed Web of Science ®Google Scholar
• TAYLOR Z, KRAKAUER H: Mortality and reoperation following prostatectomy: outcomes in a Medicare population. Urology (1991) 38(1 Suppl.):27–31.
   PubMed Web of Science ®Google Scholar
• KENNY B, BALLARD S, BLAGG J, FOX D: Pharmacological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. (1997) 40 (9):1293–1315.
   PubMed Web of Science ®Google Scholar
• ••Outlines SAR for alpha-adrenoceptor antagonists and 5-alpha reductase inhibitors.
   Google Scholar
• CAINE M: Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. (1990) 17(3):641–649.
   Google Scholar
• HEDLUND H, ANDERSSON KE, EK A: Effects of prazosin in patients with benign prostatic obstruction. J. Urol. (1983) 130 (2):275–278.
   PubMed Web of Science ®Google Scholar
• ERI LM, TVETER KJ: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. (1995) 154(3):923–934.
   PubMed Web of Science ®Google Scholar
• OESTERLING JE: Benign prostatic hyperplasia. Medical and minimally invasive treatment options. New Engl. J. Med. (1995) 332(2):99–109.
   PubMed Web of Science ®Google Scholar
• MONTIRONI R, VALLI M, FABRIS G: Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. J. Clin. Pathol. (1996) 49(4):324–328.
   PubMed Web of Science ®Google Scholar
• LEPOR H, WILLIFORD WO, BARRY MJ, et al.:The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group [see comments]. New Engl. J. Med. (1996) 335(8)533–539.
   PubMed Web of Science ®Google Scholar
• •Outlines the clinical effectiveness of alpha-adrenoceptor antagonists compared to 5-alpha reductase inhibitors.
   Google Scholar
• MCCONNELL JD, WILSON JD, GEORGE FW, et al.: Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. (1992) 74(3):505–508.
   PubMed Web of Science ®Google Scholar
• KIRBY Rs: In: Textbook of Being Prostatic hyperplasia. Kirby RS, McConnell J, Fitzpatrick J, et al. (Eds.), Isis Medical Media, Oxford (1996):566.
   Google Scholar
• TAKEDA M, HATANO A, KOMEYAMA T, et al.: Alpha-1 adrenoceptor subtypes (high, low) in human benign prostatic hypertrophy tissue according to the affinities for prazosin. Prostate (1997) 31(4):216–222.
   PubMed Web of Science ®Google Scholar
• FORD AP, ARREDONDO NF, BLUE DR, Jr. et al.: RS-17053 (N-[2-(2-eyelopropylmethoxyp henoxy) ethyl] -5 -chloro- alpha, alpha -dimethyl-1 H -indole -3 - ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol. (1996) 49(2) :209–215.
   PubMed Web of Science ®Google Scholar
• COFFEY DS, WALSH PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol. Clin. North Am. (1990) 17(3):461–475.
   PubMed Web of Science ®Google Scholar
• BRUCHOVSKY N, LESSER B, VAN DOORN E, CRAVEN S: Hormonal effects on cell proliferation in rat prostate. Vitam. Horm. (1975) 33:61–102.
   PubMedGoogle Scholar
• WHITE JW: The results of double castration in hypertrophy of the prostate. Ann. Surg. (1895) 22:1–80.
   PubMedGoogle Scholar
• IMPERATO-MCGINLEY J, GUERRERO L, GAUTIER T, PETERSON RE: Steroid 5 alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science (1974) 186(4170):1213–1215.
   PubMed Web of Science ®Google Scholar
• STEINER MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol. (1995) 153(4):1085–1096.
   PubMed Web of Science ®Google Scholar
• ERI LM, TVETER KJ: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. J. Urol. (1993) 150(1) :90–94.
   PubMed Web of Science ®Google Scholar
• MCCONNELL JD: Prostatic growth: new insights into hormonal regulation. Br. J. Urol. (1995) 76(1):5–10.
   PubMedGoogle Scholar
• RITTMASTER RS: Finasteride. New Engl. J. Med. (1994) 330(2):120–125.
   PubMed Web of Science ®Google Scholar
• ERI LM, TVETER KJ: A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J. Urol. (1993) 150(2 Pt. 1) :359–364.
   Google Scholar
• GELLER J: Overview of benign prostatic hypertrophy. Urology (1989) 34(4 Suppl.):57-63; discussion 87–96.
   Web of Science ®Google Scholar
• GINGELL JC, KNONAGEL H, KURTH KH, TUNN UW: Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J. Urol. (1995) 154(2 Pt. 1):399–401.
   PubMed Web of Science ®Google Scholar
• MCCONNELL J: Other hormonal treatments. In: Textbook of Benign Prostatic Hyperplasia. Kirby RS, McConnell J, Fitzpatrick J et al. (Eds.), Isis Medical Media, Oxford (1996):271–277.
   Google Scholar
• CULIG Z, HOBISCH A, CRONAUER MV, et al.: Regulation of prostatic growth and function by peptide growth factors. Prostate (1996) 28(6):392–405.
   PubMed Web of Science ®Google Scholar
• PEEHL DM, COHEN P, ROSENFELD RG: The insulin-like growth factor system in the prostate. World J. Urol. (1995) 13(5):306–311.
   PubMed Web of Science ®Google Scholar
• MARENGO SR, CHUNG LW: An orthotopic model for the study of growth factors in the ventral prostate of the rat: effects of epidermal growth factor and basic fibroblast growth factor. J. Androl. (1994) 15(4):2T7-286.
   Google Scholar
• TUTRONE RF, Jr., BALL RA, ORNITZ DM, et al.: Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J. Urol. (1993) 149(3) :633–639.
   PubMed Web of Science ®Google Scholar
• BUCK AC: Phytotherapy for the prostate. Br. J. Urol. (1996) 78(3):325–336.
   PubMedGoogle Scholar
• HATANO A, TANG R, WALDEN PD, LEPOR H: The alpha-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Eur. J. Pharmacol. (1996) 313(1-2):135–143.
   PubMed Web of Science ®Google Scholar
• SHIBATA K, FOGLAR R, HORIE K, et al.: KMD-3213, a novel, potent, alpha la-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol. Pharmacol. (1995) 48(2) 250–258.
   PubMed Web of Science ®Google Scholar
• MORIYAMA N, AKIYAMA K, MURATA S, et al.: KMD-3213, a novel alphalA-adrenoceptor antagonist, potently inhibits the functional alphal-adrenoceptor in human prostate. Eur. J. Pharmacol. (1997) 331(1):39–42.
   PubMed Web of Science ®Google Scholar
• TESTA R, GUARNERI L, ANGELICO P, et al.: Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-lL adrenoceptor in tissue selectivity, part II. J. Pharmacol. Exp. Ther. (1997) 281(3):1284–1293.
   PubMed Web of Science ®Google Scholar
• LEONARDI A, HIEBLE JP, GUARNERI L, et al.: Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha- 1L adrenoceptor in tissue selectivity, part I. J. Pharmacol. Exp. Ther. (1997) 281 (3):1272–1283.
   PubMed Web of Science ®Google Scholar
• BLUE DR, FORD APDW, MORGANS DJ, et al.: Preclinical pharmacology of a novel a 1A/A ecöpavoxervrop antagonist, RS-100975. Neurourol. Urodyn. (1996) 14:345–346.
   Google Scholar
• RUFFOLO RR, Jr., BONDINELL W, HIEBLE JP: Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem. (1995) 38(19):3681–3716.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, RUFFOLO RR, Jr.: Recent advances in the identification of alpha-1 and alpha-2-adrenoceptor subtypes: therapeutic implications. Exp. Opin. Invest. Drugs (1997) 6(4)367–387.
   PubMedGoogle Scholar
• HIROSUMI J, NAKAYAMA 0, CHIDA N, et al.: FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (2) In vivo effects on rat and dog prostates. J. Steroid. Biochem. Mol. Biol. (1995) 52(4):365–373.
   PubMed Web of Science ®Google Scholar
• HIROSUMI J, NAKAYAMA 0, FAGAN T, et al.: FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J. Steroid. Biochem. Mol. Biol. (1995) 52(4):357–363.
   PubMed Web of Science ®Google Scholar
• LEVY MA, BRANDT M, SHEEDY KM, et al.: Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. J. Steroid. Biochem. Mol. Biol. (1994) 48(2-3):197–206.
   PubMed Web of Science ®Google Scholar
• FRYE SV, HAFFNER CD, MALONEY PR, et al.: 6 -Azasteroids: structure-activity relationships for inhibition of Type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase. J. Med. Chem. (1994) 37(15):2352–2360.
   PubMed Web of Science ®Google Scholar
• FRYE SV, HAFFNER CD, MALONEY PR, et al.: Structure-activity relationships for inhibition of Type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3- ones: optimization of the C17 substituent. J. Med. Chem. (1995) 38(14)2621–2627.
   PubMed Web of Science ®Google Scholar
• HIRSCH KS, JONES CD, AUDIA JE, et al.: LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha- reductase Type 1. Proc. Natl. Acad. Sci. USA (1993) 90(11)5277–5281.
   PubMed Web of Science ®Google Scholar
• JONES CD, AUDIA JE, LAWHORN DE, et al.: Nonsteroidal inhibitors of human Type I steroid 5-alpha-reductase. J. Med. Chem. (1993) 36(3):421–423.
   PubMed Web of Science ®Google Scholar
• VAN HECKEN A, DEPRE M, SCHWARTZ JI, et al.: Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects. Eur. J. Clin. Pharmacol. (1994) 46 (2):123–126.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JI, LASKIN OL, MEETER CA, et al.: Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations. Clin. Pharmacol. Ther. (1994) 55(1):50–54.
   PubMed Web of Science ®Google Scholar
• DI SALLE E, BRIATICO G, GIUDICI D, et al.: Endocrine properties of the testosterone 5 alpha-reductase inhibitor turosteride (FCE 26073). J. Steroid. Biochem. Mol. Biol. (1994) 48(2-3):241–248.
   PubMed Web of Science ®Google Scholar
• PARK YC, AKIYAMA T, KURITA T, et al.: [Clinical study of TZP-4238 on patients with benign prostatic hypertrophy - with special reference to urodynamics]. Hinyokika Kiyo (1994) 40(8):761–769.
   PubMedGoogle Scholar
• KUMAMOTO Y, TSUKAMOTO T, AOKI M, et al.: [Study of clinical usefulness of an antiandrogen, TZP-4238, as a drug for treatment of benign prostatic hypertrophy - its influence on sexual function]. Hinyokika Kiyo (1994) 40(8)745–759.
   PubMedGoogle Scholar
• BERGER BM, NAADIMUTHU A, BODDY A, et al.: The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study Group. J. Urol. (1995) 154 (3):1060–1064.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-BARCENA D, VADILLO-BUENFIL M, GOMEZ-ORTA F, et al.: Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelbd in patients with benign prostatic hyperplasia and prostatic cancer. Prostate (1994) 24(2):84–92.
   PubMed Web of Science ®Google Scholar
• RADLMAIER A, EICKENBERG HU, FLETCHER MS, et al.: Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate (1996) 29(4):199–208.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, BROGDEN RN: Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging (1996) 9(5):379–395.
   PubMed Web of Science ®Google Scholar
• MASERA RG, BATEMAN A, MUSCETTOLA M, et al.: Corticostatins/defensins inhibit in vitro NK activity and cytokine production by human peripheral blood mononuclear cells. Regul. Rept. (1996) 62(1):13–21.
   PubMed Web of Science ®Google Scholar
• WEBB ML, MEEK TD: Inhibitors of endothelin. Med. Res. Rev. (1997) 17(1):17–67.
   PubMed Web of Science ®Google Scholar
• WU-WONG JR, CHIOU WJ, DICKINSON R, OPGENORTH TJ: Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J. (1997) 328:733–737.
   PubMed Web of Science ®Google Scholar
• WALDEN P, ITTMANN M, LEPOR H: The endothelin axis and prostatic hyperplasia. In: A UA. Orlando (1996).
   Google Scholar